Arbutus shareholders approve 9.5M share increase under 2016 Omnibus Plan

Arbutus Biopharma Corp

Amendment increases aggregate authorized shares by 9,500,000 common shares.
All seven director nominees (Torti, McElhaugh, Burgess, Henriques, Manchester, Meyers, Rewolinski) elected.
Non-binding advisory vote on named executive officer compensation approved (99.3M for, 13.5M against).
Ernst & Young LLP appointed as independent auditor for FY 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.